Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 25, 2016

Primary Completion Date

July 9, 2018

Study Completion Date

July 9, 2018

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

DRUG

MEDI4736 in combination with nab-paclitaxel and gemcitabine

MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion

DRUG

MEDI4736 in combination with AZD5069

MEDI4736 via IV infusion and oral AZD5069

Trial Locations (7)

Research Site, Rochester

Research Site, Cambridge

Research Site, Glasgow

Research Site, London

Research Site, London

Research Site, Manchester

Research Site, Metropolitan Borough of Wirral